KPTI ▲ +4.8% - Karyopharm Therapeutics Inc. $KPTI KPTI - Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis Karyopharm Therapeutics rose 4.8% following the company's submission of a supplemental new drug application to the FDA for a combination therapy pairing its drug XPOVIO (selinexor) with ruxolitinib to treat myelofibrosis patients. The filing represents a potential expansion of XPOVIO's market opportunity and regulatory progress, which investors viewed favorably. The stock's gains reflect optimism that the FDA may approve this new treatment approach for the blood disorder. 31-AUG-2026 07:30 AM ET